As an accomplished veteran of the biotechnology and life science fields, Lindsay Rosenwald has led the development of several biotechnology companies. Lindsay Rosenwald takes a particular interest in medical treatments related to ovarian cancer. Below, Lindsay Rosenwald describes the most recent advancements and previews how medical professionals will address this disease in the future.
Interviews and News: Where can people access updated information about ovarian cancer treatment?
Lindsay Rosenwald: The Ovarian Cancer Research Fund recently developed an intensive survey regarding the survival rate of ovarian cancer patients that revealed some interesting statistics.
Interviews and News: What is the survival rate for ovarian cancer?
Lindsay Rosenwald: The survival rate when ovarian cancer is detected early—more specifically, before it spreads beyond the ovary—is an impressive 92 percent.
Interviews and News: What about late-stage cases?
Lindsay Rosenwald: Unfortunately, ovarian cancer can be incredibly difficult to detect. In a majority of cases, ovarian cancer will not be diagnosed until its late stages.
Interviews and News: How many women are affected by ovarian cancer?
Lindsay Rosenwald: Ovarian cancer currently ranks eighth among the most prevalent cancer in women. It’s also the fifth leading cause of cancer deaths.
Interviews and News: Has the general treatment of ovarian cancer patients improved?
Lindsay Rosenwald: Although a considerable change in the cure rates for ovarian cancer has so far remained illusive, the five-year survival rate for these patients has steadily improved.
Interviews and News: To what have medical professionals attributed this trend?
Lindsay Rosenwald: This improvement in survival rates has been linked to three key trends.
Interviews and News: What’s the first trend?
Lindsay Rosenwald: First, patients more often undergo aggressive debulking surgery during the course of the disease.
Interviews and News: Explain debulking surgery.
Lindsay Rosenwald: Essentially, debulking surgery is the removal of one portion of a malignant tumor that cannot be totally excised.
Interviews and News: What’s the next trend?
Lindsay Rosenwald: Intraperitoneal treatment is more common these days.
Interviews and News: What is intraperitoneal treatment?
Lindsay Rosenwald: Intraperitoneal treatment is the delivery of anticancer drugs into the abdominal cavity.
Interviews and News: And the third and final trend?
Lindsay Rosenwald: Then, most importantly, the introduction of numerous new drugs that help in treatment has proven to be extremely beneficial.
Interviews and News: How has the survival rate improved in recent years?
Lindsay Rosenwald: Survival rates have improved tremendously in the last several decades. Now, 50 percent of women will survive longer than five years after their diagnosis.
Interviews and News: That’s an encouraging statistic.
Lindsay Rosenwald: Exactly. This is compared to a rate of 10 to 20 percent in the 1980s.
Interviews and News: What new drugs have been developed to treat ovarian cancer?
Lindsay Rosenwald: The most prominent drugs currently in the development stages are Pazopanib and PARP inhibitors. Both have the potential to be successful at ovarian cancer treatment.
Interviews and News: Thank you for your time today. This has been incredibly informative.
Lindsay Rosenwald: It’s my pleasure.
Lindsay Rosenwald is a partner and co-founder in the asset management firm Investment Partnership. Through this venture, Lindsay Rosenwald invests funds in the health-care industry, primarily in the field of biotechnology.